Nasdaq:US$16.32 (+0.02) | HKEX:HK$25.85 (-0.35) | AIM:£2.45 (-0.03)
Search
News & Press Releases
1
2
3456789
found Documents: 405
Announcement Topics, Oncology / Immunology | 14 Mar 2023

HUTCHMED Announces Closing of Fruquintinib License to Takeda Outside China
Hong Kong, Shanghai & Florham Park, NJ — Tuesday, March 14, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM, HKEX:​13) today announces that, further to its announcement on January 23, 2023 and following the completion of
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Group | 13 Mar 2023

HUTCHMED Confirms No Assets Held at Silicon Valley Bank
Hong Kong, Shanghai & Florham Park, NJ — Monday, March 13, 2023: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM, HKEX:13) today confirms that it does not have any exposure to Silicon Valley Bank (“SVB”) or Si
Read More
View Press Release (PDF)
Announcements & Press Releases, Group | 28 Feb 2023

HUTCHMED Reports 2022 Full Year Results and Provides Business Updates
Landmark licensing deal with Takeda for fruquintinib outside of China, bringing HUTCHMED up to US$1.13 billion, plus royalties, and demonstrating execution of the new global strategy Record Full Year 2022 oncology/immunology revenues driven by sign
Read More
HKEX Announcement (PDF)LSE RNS Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 27 Feb 2023

HUTCHMED Completes Patient Enrollment of Phase II Registration Trial of Amdizalisib in Follicular Lymphoma in China
Hong Kong, Shanghai & Florham Park, NJ — Monday, February 27, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM, HKEX:​13) today announces that it has completed patient enrollment of Phase II registration trial of amdizalisib
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Group | 31 Jan 2023

HUTCHMED to Announce 2022 Final Results
Hong Kong, Shanghai & Florham Park, NJ — Tuesday, January 31, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year ended December 31, 2022 on Tuesday, February 28, 2023 at
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 23 Jan 2023

HUTCHMED Announces License to Takeda to Develop and Commercialize Fruquintinib Outside China
— HUTCHMED to receive US$400 million upfront on deal closing and up to US$730 million in potential future milestone payments, totaling up to US$1.13 billion, plus royalties on net sales — — Marketing authorization submissions in the U.S., Eur
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 18 Jan 2023

HUTCHMED Announces Agreement with NHSA for Inclusion of ORPATHYS® in the National Reimbursement Drug List in China
Hong Kong, Shanghai & Florham Park, NJ –– Wednesday, January 18, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX:13) today announces, following negotiations with the China National Healthcare Security Administration (
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 3 Jan 2023

HUTCHMED Completes Patient Enrollment of ESLIM-01, a Phase III Trial of Sovleplenib in Primary Immune Thrombocytopenia in China
Hong Kong, Shanghai & Florham Park, NJ — Tuesday, January 3, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM, HKEX:​13) today announces that it has completed patient enrollment of ESLIM-01, a pivotal Phase III clinical tria
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 19 Dec 2022

HUTCHMED Initiates Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Colorectal Cancer
— Company plans to complete rolling submission to the U.S. in the first half of 2023, followed by filings in Europe and Japan — — NDA is supported by global Phase III FRESCO-2 study conducted in the U.S., Europe, Japan and Australia — — F
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Group | 15 Nov 2022

HUTCHMED Announces Strategy to Focus on Late-Stage Pipeline Regulatory Approvals
Reprioritization accelerating path to profitability Evaluation of partnership opportunities for select late-stage assets   Hong Kong, Shanghai & Florham Park, NJ — Tuesday, November 15, 2022: HUTCHMED (China) Limited (“HUTCHMED”)
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 14 Nov 2022

HUTCHMED Announces Positive Topline Result in Fruquintinib Phase III FRUTIGA Study in Second-Line Gastric Cancer in China
— Results of dual primary endpoint study showed statistically significant and clinically meaningful benefit in progression-free survival, a primary endpoint — — Overall survival, the other primary endpoint, was not statistically significant
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 27 Oct 2022

HUTCHMED Initiates a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China
Hong Kong, Shanghai & Florham Park, NJ — Thursday, October 27, 2022: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a Phase II/III trial of fruquintinib in combination with sintilimab a
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 10 Oct 2022

HUTCHMED Initiates a Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China
Hong Kong, Shanghai & Florham Park, NJ –– Monday, October 10, 2022: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a Phase II/III trial of sovleplenib in adult patients with warm anti
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 8 Sep 2022

HUTCHMED Highlights Phase III FRESCO-2 MRCT Data Summary of Fruquintinib in Refractory Metastatic Colorectal Cancer from the Upcoming ESMO 2022 Presentation
— Fruquintinib treatment reduced the risk of death by 34% in metastatic colorectal cancer (0.66 HR) — — Increased disease control with risk of disease progression or death reduced by 68% (0.32 HR) — — Results to be presented in a late-b
Read More
View Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 23 Aug 2022

HUTCHMED Highlights Fruquintinib MRCT FRESCO-2 Data to be Presented at the Upcoming ESMO Congress 2022
— Trial met primary endpoint of overall survival and all secondary endpoints — — Selected as a late-breaker presentation — — Conference call and webcast to be held on Monday, September 12 at 2:00 pm Paris time to review the presentation a
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 9 Aug 2022

Inmagene and HUTCHMED Announce First Participant in Global Phase I Trial of IMG-004
San Diego, Shanghai and Hong Kong — Tuesday, August 9, 2022: Inmagene Biopharmaceuticals ("Inmagene") and HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) announce today that the first participant, based in the United State
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 8 Aug 2022

HUTCHMED Announces that Fruquintinib Global Phase III FRESCO-2 Study Has Met Its Primary Endpoint in Metastatic Colorectal Cancer
— Trial met primary endpoint of overall survival and all secondary endpoints — — Overall safety consistent with fruquintinib known profile — — Plans for regulatory submissions underway in the U.S., Europe and Japan — — Results to
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 8 Aug 2022

HUTCHMED and AstraZeneca Announce that TAGRISSO® Plus Savolitinib Demonstrated 49% Objective Response Rate in Lung Cancer Patients with High Levels of MET Overexpression and/or Amplification in SAVANNAH Phase II Trial
— MET is the most common biomarker in patients with EGFR-mutated lung cancer who develop resistance to targeted therapy — — Global SAFFRON Phase III trial evaluating this combination is underway —   Hong Kong, Shanghai & Florh
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Group | 1 Aug 2022

HUTCHMED Reports 2022 Interim Results and Provides Business Updates
Oncology/Immunology revenues up 113% to $91.1 million, due to ELUNATE®, SULANDA® and ORPATHYS® growth First presentation of SAVANNAH data showing 52% response rate and 9.6 month duration of response in 2L+ post-TAGRISSO® NSCLC1 patients with hig
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 1 Aug 2022

HUTCHMED Initiates a Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in China
Hong Kong, Shanghai & Florham Park, NJ — Monday, August 1, 2022: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that it has initiated a bridging study of tazemetostat in China. The first patient receiv
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 15 Jul 2022

HUTCHMED Initiates Phase I Trial of Anti-CD47 Monoclonal Antibody HMPL-A83 in Patients with Advanced Malignant Neoplasms in China
— HMPL-A83 is the thirteenth innovative oncology drug candidate discovered in-house by HUTCHMED and its second large molecule drug candidate to enter clinical studies — Hong Kong, Shanghai & Florham Park, NJ — Friday, July 15, 2022: HUTCH
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 13 Jul 2022

HUTCHMED Highlights First Presentation of Results of the SAVANNAH Global Phase II Trial of Savolitinib plus TAGRISSO® at the 2022 WCLC Annual Meeting
— 49% ORR amongst SAVANNAH patients with higher MET levels — Hong Kong, Shanghai & Florham Park, NJ — Wednesday, July 13, 2022: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces the first presentation of
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 6 Jul 2022

Inmagene and HUTCHMED Announce First Participants in Global Phase I Trial of IMG-007
San Diego, Shanghai, Hong Kong and Sydney — Wednesday, July 6, 2022: Inmagene Biopharmaceuticals ("Inmagene") and HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) announce today that the first participant, based in Australi
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Group | 27 Jun 2022

HUTCHMED to Announce 2022 Half-Year Financial Results
Hong Kong, Shanghai & Florham Park, NJ — Monday, June 27, 2022: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its interim results for the six months ended June 30, 2022 on Monday, August 1, 2022 at 7:00
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 1 Jun 2022

HUTCHMED Announces TAZVERIK® Approved to be Used in Hainan Pilot Zone in China
Hong Kong, Shanghai & Florham Park, NJ — Wednesday, June 1, 2022: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that TAZVERIK® (tazemetostat) has been approved by the Health Commission and Medical Pr
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Group, Regulatory Notice | 30 May 2022

Notice of Publication of 2021 Sustainability Report
The English and Chinese versions of the 2021 Sustainability Report (the “Sustainability Report”) are available on the website of the Company at www.hutch-med.com and that of Hong Kong Exchanges and Clearing Limited (“HKEx”) at www.hkexnews.hk
Read More
HKEX Notification Letter (PDF)2021 Sustainability Report
Announcements & Press Releases, Oncology / Immunology, Press Releases | 2 May 2022

HUTCHMED Receives Complete Response Letter from the U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors
HUTCHMED to hold a conference call at 8:00 am EDT / 1:00 pm BST / 8:00 pm HKT   Hong Kong, Shanghai & Florham Park, NJ — Monday, May 2, 2022: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM; HKEX:13) anno
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Group | 31 Mar 2022

Update on Status under Holding Foreign Companies Accountable Act
Hong Kong, Shanghai & Florham Park, NJ — Thursday, March 31, 2022: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM; SEHK:13) provides an update on its status under the Holding Foreign Companies Accountable Act (th
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Group | 23 Mar 2022

2021 Annual Report and Notice of Annual General Meeting
Hong Kong, Shanghai, & Florham Park, NJ — Wednesday, March 23, 2022: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX:13) today announces that its 2021 Annual Report together with the Notice of Annual General Meeting and the For
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Group | 11 Mar 2022

Update on Status under Holding Foreign Companies Accountable Act
Hong Kong, Shanghai & Florham Park, NJ — Friday, March 11, 2022: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM; SEHK:13) would like to provide an update on its status under the Holding Foreign Companies Account
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 7 Mar 2022

HUTCHMED Receives a US$15 million Milestone from AstraZeneca for Initiating Start-up Activities for a Global Phase III Study of ORPATHYS® in Lung Cancer
Hong Kong, Shanghai & Florham Park, NJ — Monday, March 7, 2022: (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that it has received a US$15 million milestone payment from AstraZeneca PLC (“AstraZeneca”) (LSE/STO/Nasdaq:​
Read More
HKEX Announcement (PDF)LSE RNS Announcement (PDF)
Announcements & Press Releases, Group | 3 Mar 2022

HUTCHMED announces retirement of CEO and appointment of new CEO
Hong Kong, Shanghai & Florham Park, NJ – Thursday, March 3, 2022: (“HUTCHMED” or the “Company”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces: the retirement of Mr. Christian Hogg after almost 22 years with the Company, including
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Group | 3 Mar 2022

HUTCHMED Reports 2021 Full Year Results and Provides Business Updates
Oncology/Immunology revenues up 296% to $119.6 million, due to ELUNATE® growth and the 2021 launches of SULANDA® and ORPATHYS®; Positive SAVANNAH, CALYPSO and VIKTORY studies triggered five registration studies on ORPATHYS® in lung cancer, kidne
Read More
HKEX Announcement (PDF)LSE RNS Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 1 Mar 2022

HUTCHMED Receives Approval to Commercialize ELUNATE® in Macau
— First homegrown innovative medicine approved in Macau based on China clinical data — Hong Kong, Shanghai & Florham Park, NJ –– Tuesday, March 1, 2022: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today an
Read More
LSE RNS Announcement (PDF)HKEX – Voluntary Announcement (PDF)
Announcements & Press Releases, Group | 7 Feb 2022

HUTCHMED to Announce 2021 Final Results
Hong Kong, Shanghai & Florham Park, NJ — Monday, February 7, 2022: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year ended December 31, 2021 on Thursday, March 3, 2022 at 7:00
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 4 Feb 2022

HUTCHMED Initiates Phase Ib/II Study of HMPL-453 in Combination with Chemotherapy or Toripalimab for Advanced Solid Tumors in China
Hong Kong, Shanghai & Florham Park, NJ — Friday, February 4, 2022: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a Phase Ib/II study in China of HMPL-453, an investigational novel sele
Read More
LSE RNS Announcement (PDF)HKEX – Voluntary Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 20 Jan 2022

HUTCHMED Initiates a Phase I Trial of HMPL-653 in Patients with Advanced Malignant Solid Tumors and TGCT in China
Hong Kong, Shanghai & Florham Park, NJ –– Thursday, January 20, 2022: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a Phase I trial in China of HMPL-653, an investigational novel, hi
Read More
LSE RNS Announcement (PDF)HKEX – Voluntary Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 19 Jan 2022

HUTCHMED Highlights Fruquintinib Clinical Data to be Presented at the 2022 ASCO Gastrointestinal Cancers Symposium
Hong Kong, Shanghai & Florham Park, NJ — Wednesday, January 19, 2022: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that updated analysis of the ongoing international Phase I/Ib trial of fruquintinib will
Read More
LSE RNS Announcement (PDF)HKEX – Voluntary Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 12 Jan 2022

HUTCHMED Receives Breakthrough Therapy Designation in China for HMPL-523 for Treatment of Primary Immune Thrombocytopenia
Hong Kong, Shanghai & Florham Park, NJ –– Wednesday, January 12, 2022: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that the Center for Drug Evaluation of China’s National Medical Products Admin
Read More
LSE RNS Announcement (PDF)HKEX – Voluntary Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 10 Jan 2022

HUTCHMED Initiates Phase I Study of BTK Inhibitor HMPL-760 in Patients with Previously Treated B-Cell Non-Hodgkin Lymphoma in China
— HMPL-760 is the eleventh innovative potential oncology drug candidate discovered in-house by HUTCHMED — — HMPL-760 is HUTCHMED’s fifth candidate in clinical development for hematological malignancies, including amdizalisib and HMPL-523 t
Read More
HKEX – Voluntary Announcement (PDF)LSE RNS Announcement (PDF)
Announcements & Press Releases, Group | 20 Dec 2021

HUTCHMED Included in FTSE Russell Indexes
Hong Kong, Shanghai & Florham Park, NJ — Monday, December 20, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has been included by FTSE Russell in the FTSE Global Equity Index Series (“GEIS”
Read More
LSE RNS Announcement (PDF)HKEX – Voluntary Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 14 Dec 2021

HUTCHMED Highlights HMPL-523 Clinical Data Presented at the 2021 ASH Annual Meeting
Hong Kong, Shanghai & Florham Park, NJ — Tuesday, December 14, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces new analyses on the ongoing studies of HMPL-523 presented at the 63rd American Society for
Read More
HKEX – Voluntary Announcement (PDF)LSE RNS Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 10 Dec 2021

HUTCHMED Highlights Surufatinib and Toripalimab Combination Clinical Data being Presented at the ESMO Immuno-Oncology 2021 Meeting
Hong Kong, Shanghai & Florham Park, NJ — Friday, December 10, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new analyses and updates on the ongoing studies of surufatinib combined with toripalima
Read More
LSE RNS Announcement (PDF)HKEX – Voluntary Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 6 Dec 2021

HUTCHMED Completes Planned Enrollment of FRESCO-2, a Global Phase III Trial of Fruquintinib in Metastatic Colorectal Cancer
— Recruitment of 687 patients globally completed in fifteen months, ahead of schedule — — FRESCO-2 primary objective is to confirm overall clinical benefit seen in the China FRESCO pivotal study[1], and to support global registrations —
Read More
HKEX – Voluntary Announcement (PDF)LSE RNS Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 3 Dec 2021

HUTCHMED Announces Agreement with NHSA for Continued Inclusion of ELUNATE® and Addition of SULANDA® in the National Reimbursement Drug List in China
Hong Kong, Shanghai & Florham Park, NJ –– Friday, December 3, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX:13) today announces that, following the 2021 negotiations with the China National Healthcare Security Adminis
Read More
HKEX - INSIDE INFORMATION (PDF)LSE RNS Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 24 Nov 2021

HUTCHMED and AstraZeneca Initiate SACHI Phase III Trial of ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients in China After Progression on EGFR Inhibitor Therapy
— Follows important findings from the TATTON[1] study of the combination in EGFR inhibitor refractory lung cancer patients whose tumors harbor aberrations of MET — Hong Kong, Shanghai & Florham Park, NJ — Wednesday, November 24, 2021: H
Read More
LSE RNS Announcement (PDF)HKEX - Voluntary Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 8 Nov 2021

HUTCHMED Highlights HMPL-523 Clinical Data to be Presented at the 2021 ASH Annual Meeting
Hong Kong, Shanghai & Florham Park, NJ — Monday, November 8, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new analyses and updates on the ongoing studies of HMPL-523 and HMPL-306 will be present
Read More
LSE RNS Announcement (PDF)HKEX – Voluntary Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 1 Nov 2021

HUTCHMED and AstraZeneca Initiate SAMETA Global Phase III Trial of Savolitinib in Combination with PD-L1 Inhibitor IMFINZI® in Patients with MET-Driven Advanced Papillary Renal Cell Carcinoma
— Follows multiple global studies of savolitinib in papillary renal cell carcinoma patients including SAVOIR and CALYPSO — — In CALYPSO, savolitinib and IMFINZI® combination demonstrated a 57% confirmed response rate in PRCC patients with
Read More
HKEX – Voluntary Announcement (PDF)LSE RNS Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 28 Oct 2021

HUTCHMED Initiates ESLIM-01, a Phase III Trial of HMPL-523 in Patients with Immune Thrombocytopenia in China
Hong Kong, Shanghai & Florham Park, NJ –– Thursday, October 28, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a Phase III trial in China of HMPL-523, a novel, investigational s
Read More
HKEX – Voluntary Announcement (PDF)LSE RNS Announcement (PDF)
2021, Announcements & Press Releases, Oncology / Immunology | 29 Sep 2021

HUTCHMED Highlights Oral Presentations at 2021 Chinese Society of Clinical Oncology Annual Meeting
Hong Kong, Shanghai & Florham Park, NJ — Wednesday, September 29, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM, HKEX: 13) announces that new and updated clinical data from several ongoing combination studies of surufatinib (
Read More
LSE RNS Announcement (PDF)HKEX – Voluntary Announcement (PDF)
1
2
3456789